Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Comms

- PMLiVE

GSK’s Jemperli combination shows promise in phase 3 endometrial cancer trial

Up to 20% of endometrial cancer patients will have advanced disease at the time of diagnosis

- PMLiVE

Novartis’ Cosentyx recommended by NICE for hidradenitis suppurativa

At least 200,000 people in the UK are affected by the inflammatory skin disease

- PMLiVE

AbbVie’s Parkinson’s disease therapy recommended by NICE for advanced disease

Around 900 adults with advanced Parkinson’s are set to benefit from Produodopa

- PMLiVE

GSK’s RSV vaccine Arexvy shows promise in adults aged 50 to 59 years

Arexvy has already been approved in the US and Europe to protect those aged 60 years and older

- PMLiVE

Bristol Myers Squibb’s subcutaneous Opdivo shows promise in kidney cancer trial

More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

- PMLiVE

Takeda announces EC approval for Adcetris combination in Hodgkin lymphoma

The ADC has been approved alongside doxorubicin, vinblastine and dacarbazine

- PMLiVE

AbbVie announces positive results from head-to-head study of Skyrizi in Crohn’s disease

The late-stage trial has been evaluating the IL-23 inhibitor against Johnson & Johnson’s Stelara

- PMLiVE

Bristol Myers Squibb’s Opdivo approved by FDA for expanded melanoma use

More than 97,000 cases of melanoma are expected to be diagnosed in the US in 2023

- PMLiVE

GSK survey results highlight meningitis knowledge gaps among parents

More than 90% of parents did not know all three common symptoms of the infection

- PMLiVE

BMS shares positive three-year results for Sotyktu in plaque psoriasis

Up to 100 million people worldwide are affected by some form of the immune-mediated disease

- PMLiVE

BMS shares positive long-term data for Zeposia in relapsing multiple sclerosis

Approximately 2.5 million people worldwide are affected by the neurological disease

- PMLiVE

Bristol Myers Squibb to acquire Mirati Therapeutics for up to $5.8bn

The transaction would mark a significant boost to the US drugmaker’s oncology portfolio

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links